

BSW Formulary Update - September 2020

New additions to the BSWformulary

- [Memantine orodispersible tablets and oral solution](#) to be used in line with updated SCA (below) Amber TLS
- [Fulvestrant \(Faslodex®\)](#) RED TLS to be used in line with relevant NICE TAs

New and Updated Shared Care Agreements

- **Updated** – [AWP SCA for the treatment of Alzheimer's disease: donepezil, rivastigmine, galantamine and memantine](#)
Note: For **BaNES and Wiltshire patients ONLY**. In Swindon prescribing remains with the specialist memory clinic.

Deferred decisions

- Omeprazole 2mg/ml and 4mg/ml Powder for Oral Suspension (Rosemont). Omeprazole suspension is not included on the BSWformulary for adults as several licensed and more cost-effective alternative formulations are already in established use. Further review is required before a recommendation can be made for use in paediatrics.

Minor changes to previous (BCAP/3TS/ICID) formularies to align for BSWformulary

- [Patiromer sorbitex calcium](#) (Veltassa 8.4g, 16.8g, 25.2g powder for oral suspension). Red TLS for all areas.
- [Polystyrene sulphonate resins](#) (Calcium resonium powder for suspension). Red TLS for all areas.

Removed from formulary

- [Danazol 100mg and 200mg capsules](#) discontinued in June 2020 in the UK.

What BSW CCG formulary team are working on

- Producing a policy/pathway and prescribing criteria for use of melatonin
- Updating the over active bladder (OAB) pathway
- Producing a consensus statement for newly license liquid omeprazole in paediatrics
- Oxycodone and fentanyl preparations: Aligning TLS across BSW for different indications
- Updating the Vitamin D guidance
- Updating the Vitamin B12 guidance
- Updating the domperidone guidance
- Updating the pain management documents
- Reviewing the use of Cox-2 inhibitors across BSW and producing guidance

- Producing guidance for primary care on aphthous ulcers and on the treatment of acute otitis externa
- Reviewing the use of rifampicin across BSW
- Reviewing the use of LMWH across BSW
- Writing position statements on various devices
- Aligning Shared Care Agreements across BSW starting with document on DMARD monitoring
- Refining a chapter review process for BSW formulary and further development of the paediatric section of the BSW formulary.

From September 2020, changes to the BSW joint formulary will be agreed and minuted through the monthly Area Prescribing Committee (APC) meetings and communicated via newsletter, teamsnet and via the APC recent decisions tab [here](#). The BSW joint formulary is still under construction and is designed to be an evolving, dynamic resource. We are working to ensure the messages on GP prescribing systems are in line with the joint formulary. If you discover information you believe to be inaccurate or misleading please contact us at bswccg.formulary@nhs.net